Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23728172 | 0.86 | CHRM2 (0.42) | CHRM2CHRM1GPR119USP30MAPT | |
| SCHEMBL23744307 | 0.85 | GPR119 (0.47) | CHRM2CHRM1GPR119STS | |
| SCHEMBL23744182 | 0.85 | GPR119 (0.47) | CHRM2CHRM1GPR119STS | |
| SCHEMBL23744453 | 0.83 | CHRM2 (0.56) | CHRM2CHRM1CHRM3 | |
| SCHEMBL23744512 | 0.83 | CHRM2 (0.56) | CHRM2CHRM1CHRM3 | |
| SCHEMBL23744194 | 0.83 | CHRM2 (0.49) | CHRM2CHRM1GPR119EPHX1HDAC4 | |
| SCHEMBL31027274 | 0.82 | CHRM2 (0.46) | CHRM2CHRM1GPR119CHRM3 | |
| SCHEMBL23744599 | 0.81 | CHRM1 (0.54) | CHRM2CHRM1CHRM3 | |
| SCHEMBL23744641 | 0.81 | CHRM1 (0.54) | CHRM2CHRM1CHRM3 | |
| SCHEMBL23744421 | 0.81 | CHRM2 (0.58) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | CHRM2 2/4885CHRM1 5/4885GPR119 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.